Integrated molecular landscape of Parkinson’s disease

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  T. Postmus.  Genetics of Parkinson's disease , 2018 .

[3]  C. Sankhla,et al.  Oxidative stress and Parkinson's disease , 2017, Neurology India.

[4]  B. Franke,et al.  An integrated molecular landscape implicates the regulation of dendritic spine formation through insulin-related signalling in obsessive-compulsive disorder. , 2016, Journal of psychiatry & neuroscience : JPN.

[5]  S. Männistö,et al.  Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease. , 2015, Parkinsonism & related disorders.

[6]  C. Meyers,et al.  The loss of glucose-regulated protein 78 (GRP78) during normal aging or from siRNA knockdown augments human alpha-synuclein (α-syn) toxicity to rat nigral neurons , 2015, Neurobiology of Aging.

[7]  O. Isacson.  Lysosomes to combat Parkinson's disease , 2015, Nature Neuroscience.

[8]  Dongfeng Zhang,et al.  Macronutrients intake and risk of Parkinson's disease: A meta‐analysis , 2015, Geriatrics & gerontology international.

[9]  Richard Wade-Martins,et al.  Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.

[10]  J. Haines,et al.  Vitamin D from different sources is inversely associated with Parkinson disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[11]  Xuemei Huang,et al.  Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[12]  Jack Euesden,et al.  PRSice: Polygenic Risk Score software , 2014, Bioinform..

[13]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[14]  Heang-Ping Chan,et al.  Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk , 2022 .

[15]  P. Muglia,et al.  Genome-wide association study of bipolar disorder in Canadian and UK populations corroborates disease loci including SYNE1 and CSMD1 , 2014, BMC Medical Genetics.

[16]  R. Cilia,et al.  Cardiometabolic factors and disease duration in patients with Parkinson's disease. , 2013, Nutrition.

[17]  P. Svenningsson,et al.  Oxysterols and Parkinson's disease: Evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease , 2013, Neuroscience Letters.

[18]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[19]  Kai Wang,et al.  Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients , 2013, PloS one.

[20]  D. Berg,et al.  Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study , 2013, PloS one.

[21]  A. Lahad,et al.  Long-term statin use and the risk of Parkinson's disease. , 2013, The American journal of managed care.

[22]  B. Franke,et al.  AKAPs integrate genetic findings for autism spectrum disorders , 2013, Translational Psychiatry.

[23]  M. Urashima,et al.  Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. , 2013, The American journal of clinical nutrition.

[24]  Chin-Shang Li,et al.  Plasma testosterone is associated with Framingham risk score , 2012, The aging male : the official journal of the International Society for the Study of the Aging Male.

[25]  D. Hernandez,et al.  Genome Wide Assessment of Young Onset Parkinson’s Disease from Finland , 2012, PloS one.

[26]  P. McLean,et al.  Protein degradation pathways in Parkinson’s disease: curse or blessing , 2012, Acta Neuropathologica.

[27]  A. Hoofnagle,et al.  Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men , 2012, Steroids.

[28]  Xiang Gao,et al.  Prospective study of statin use and risk of Parkinson disease. , 2012, Archives of neurology.

[29]  O. Isacson,et al.  Viral and Inflammatory Triggers of Neurodegenerative Diseases , 2012, Science Translational Medicine.

[30]  D. Konukoğlu,et al.  Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease , 2012, Acta Neurologica Belgica.

[31]  S. Chrapusta,et al.  cGMP level in idiopathic Parkinson's disease patients with and without cardiovascular disease - A pilot study. , 2011, Parkinsonism & related disorders.

[32]  Karen Marder,et al.  Genome-Wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population , 2011, BMC Medical Genetics.

[33]  D. Hernandez,et al.  Genome-wide association study confirms extant PD risk loci among the Dutch , 2011, European Journal of Human Genetics.

[34]  Nicholas Eriksson,et al.  Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.

[35]  B. Franke,et al.  Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. , 2011, The American journal of psychiatry.

[36]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[37]  Mohamad Saad,et al.  Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. , 2011, Human molecular genetics.

[38]  Matti Pirinen,et al.  Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21 , 2010, Human molecular genetics.

[39]  J. Nutt,et al.  Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.

[40]  J. Olsen,et al.  Statin use and Parkinson's disease in Denmark , 2010, Movement disorders : official journal of the Movement Disorder Society.

[41]  H. Fukuyama,et al.  Case–control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan , 2010, Journal of the Neurological Sciences.

[42]  V. Gundersen,et al.  Protein aggregation in Parkinson’s disease , 2010, Acta neurologica Scandinavica. Supplementum.

[43]  Carol Coupland,et al.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.

[44]  N. Cox,et al.  Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS , 2010, PLoS genetics.

[45]  Joseph K. Pickrell,et al.  Understanding mechanisms underlying human gene expression variation with RNA sequencing , 2010, Nature.

[46]  Eden R Martin,et al.  Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.

[47]  Y. Chan,et al.  Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. , 2010, Free radical biology & medicine.

[48]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[49]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[50]  H. Forta,et al.  The relation of testosterone levels with fatigue and apathy in Parkinson's disease , 2009, Clinical Neurology and Neurosurgery.

[51]  J. Gilbert,et al.  A Genome‐wide Association Study of Autism Reveals a Common Novel Risk Locus at 5p14.1 , 2009, Annals of human genetics.

[52]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[53]  D. Avramopoulos,et al.  Orientation, distance, regulation and function of neighbouring genes , 2009, Human Genomics.

[54]  B. Carleton,et al.  Statin use and the risk of Parkinson disease: a nested case control study , 2008, Journal of Clinical Neuroscience.

[55]  M. Stephens,et al.  High-Resolution Mapping of Expression-QTLs Yields Insight into Human Gene Regulation , 2008, PLoS genetics.

[56]  Xuemei Huang,et al.  Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu‐Asia Aging Study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[57]  B. Ritz,et al.  Statin use and the risk of Parkinson disease , 2008, Neurology.

[58]  Richard W. Murrow,et al.  Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[59]  Albert Hofman,et al.  Serum cholesterol levels and the risk of Parkinson's disease. , 2006, American journal of epidemiology.

[60]  Sonja W. Scholz,et al.  Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.

[61]  A. A. Farooqui,et al.  Lovastatin Modulates Increased Cholesterol and Oxysterol Levels and Has a Neuroprotective Effect on Rat Hippocampal Neurons After Kainate Injury , 2006, Journal of neuropathology and experimental neurology.

[62]  Michael S Okun,et al.  Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. , 2006, Archives of neurology.

[63]  J. Kong,et al.  Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. , 2006, American journal of physiology. Endocrinology and metabolism.

[64]  Mariza de Andrade,et al.  High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.

[65]  A. Zwinderman,et al.  LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study , 2005, Current medical research and opinion.

[66]  J. Grace,et al.  Testosterone deficiency and apathy in Parkinson’s disease: a pilot study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[67]  M. Okun,et al.  Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. , 2002, Archives of neurology.

[68]  Takeshi Iwatsubo,et al.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.

[69]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[70]  D. Benson,et al.  Alzheimer's disease and Parkinson's disease , 1988, Neurology.

[71]  V. Bonifati.  Genetics of Parkinson's disease--state of the art, 2013. , 2014, Parkinsonism & related disorders.

[72]  C. Wider,et al.  Genetics of Parkinson's disease: the yield. , 2014, Parkinsonism & related disorders.

[73]  Katunina Ea,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[74]  J. Gusella,et al.  Genomewide Association Study for Onset Age in Parkinson Disease , 2009 .

[75]  S. Jick,et al.  Use of Statins and the Risk of Parkinson’s Disease , 2008, Drug safety.

[76]  Lewis E Kazis,et al.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.

[77]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .